| 1 |
34817825 | Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients. | 2021 Dec |
3 |
| 2 |
27216792 | Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450. | 2016 |
1 |
| 3 |
14586391 | Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype. | 2003 Nov |
1 |
| 4 |
11908770 | CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro. | 2001 |
6 |
| 5 |
10877007 | In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. | 2000 May |
1 |